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Copyright © 2009 JCBN Summary Recent reports described a high incidence of nonalcoholic steatohepatitis (NASH)
in patients with obstructive sleep apnea. Accordingly, we hypothesized that recurrent and
intermittent hypoxemia plays an important role in the pathogenesis of NASH. Our objective
was construction of a practical and accurate experimental model to reproduce the key features
of NASH in humans. Chemical hypoxemia through methemoglobinemia was induced by daily
intraperitoneal injection of sodium nitrite (40 mg/kg) for 4 weeks in rats with fatty liver. The
later was induced by 4-week feeding a choline-deficient high-fat diet (CDHF). Besides, the
normal chow diets feeding groups were prepared with in the same manner except for CDHF
feeding. The animal experiment was performed in four groups; Normal control, Hypoxemia,
CDHF, and CDHF + hypoxemia. Nitrite was given for the later 4 weeks to each rat of
Hypoxemia and CDHF + hypoxemia. CDHF + hypoxemia rats were confirmed to develop histo-
logical changes that resemble those of patients with NASH, together with biochemical liver
dysfunction, while CDHF group was limited in mild steatosis, and Hypoxemia group liver was
normal. Present study established a reproducible and useful NASH model resembling the main
features of NASH in humans, and showed first that recurrent and intermittent hypoxemia
aggravate fatty liver to steatohepatitis and liver fibrosis.
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Introduction
Nonalcoholic steatohepatitis (NASH) is a progressive
liver disorder that occurs in patients without significant
alcohol consumption, and, histologically, it resembles
alcoholic liver disease with macrovesicular steatosis, spotty
necrosis, inflammation and fibrosis [1, 2].
Animal models have greatly contributed to the under-
standing of NASH [3–5]. Such models include rats that are
treated for up to one year [6] or rats that are fed choline-
and methionine-free diet [7], a nutritional deficiency to
which rodents are highly sensitive but which is not common
in patients with NASH. However, until recently, the study of
therapeutics for NASH has been difficult because of the
lack of a suitable experimental model.
Patients with obstructive sleep apnea (OSA) suffer from
potentially severe hypoxemia due to repetitive airway
obstruction during sleep, and are at risk of development of
fatty liver as a result of obesity [8]. There is also evidence
that OSA per se could be a risk factor for liver injury;
ischemic hepatitis during OSA has been reported [9, 10].
Here we describe a new and more clinically-relevant
rat model of NASH. Rats were fed a choline-deficientF. Takayama et al.
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fat-rich diet and made hypoxemic to induce within a rela-
tively short period of time liver dysfunction that resembled
NASH. We present the histological and biochemical changes
induced by the above treatment.
Materials and Methods
Animals
Six-week-old male Wistar rats were purchased from
Shimizu Animal. Co. (Kyoto, Japan) and maintained at the
Okayama University animal facility in accordance with the
Okayama University Guidelines on the Care and Use of
Laboratory Animals. Rats were housed in individual cages
in air-conditioned rooms with controlled 12-h light-dark
cycle. The rats were allowed to acclimate to the animal
facility and provided free access to diets and water ad
libitum.
Experimental design
At 10 weeks of age, the animals were divided into two
groups and fed either control normal diets or choline-
deficient high-fat (CDHF) diets (Oriental Yeast Co., Tokyo,
Japan) for 4 weeks. At the end of this period, rats of the
Normal control group continued to be fed normal chow (MF
laboratory chow, Oriental Yeast Co., Tokyo, Japan). On the
other hand, rats of the CDHF + hypoxemia group received
CDHF diets for another 4 weeks and treated during this
period with intraperitoneal injection of 40 mg/kg of sodium
nitrite (NaNO2) every day to induce methemoglobinemia
[11]. Rats of the Hypoxemia group were fed standard diets
for another 4 weeks without NaNO2.
Collection of biological samples
At the end of the 8-week experimental period, the rats
were sacrificed under light ether anesthesia, blood was
collected from the inferior vena cava for serum analysis, and
livers were resected for histopathological and biochemical
analyses. In addition, blood samples were also drawn under
light ether anesthesia, every week during the experimental
feeding period. Besides, after the single intraperitoneal
administration of 40 mg/kg NaNO2 to rats fed with 4 weeks
CDHF diets, the arterial bloods were drawn with time from
femoral arteries cannulated with silicon tubes, and were kept
on ice until determining the partial pressure of oxygen and
the methemoglobin level.
Biochemical analysis
Serum biochemical markers, AST, ALT, γ-GTP, trigly-
cerides and ALP were determined spectrophotometrically
by using standard kits (Wako Pure Chemical Industries,
Osaka, Japan). The levels of hyaluronic acid were measured
in serum samples and liver homogenates using ELISA kits
(SEIKAGAKU Corporation, Tokyo, Japan). Arterial partial
pressure of oxygen was determined within 15 min of blood
being drawn, with a blood gas analyzer (IRMA SL 2000,
Diametrics Medical, Tokyo). The methemoglobin level was
determined spectrophotometrically [11]. Blood glucose was
determined by the glucose-oxidase method using Glucocard
(Aventis Pharma, Tokyo, Japan).
Histological examination
Liver tissues were collected then fixed overnight in 10%
formaldehyde in phosphate-buffered saline, then dehydrated
and embedded in paraffin. Liver tissue sections (4 μm thick)
were stained with hematoxylin and with Masson trichrome
(MT) staining for histological examination.
Statistical analysis
Data are expressed as mean ± SEM of five rats. Differ-
ences among groups were examined by one-way analysis
of variance (ANOVA) followed by Dunnett’s multiple
comparison test. A p value less than 0.05 was considered
statistically significant.
Results
Arterial partial pressure of oxygen and methemoglobin
formation in rats fed choline-deficient hyper-fat diets and
with intraperitoneal single NaNO2 injection
After the intraperitoneal single 40 mg/kg NaNO2 injection
to the rats fed CDHF for 4 weeks, in an arterial blood, there
was induced the methemoglobin formation at the level of
approximately 4 g/dL in within 15 min of injection, followed
by a decrease to less than 1 g/dL at 2 h later. The blood
methemoglobin concentrations correlated inversely with
arterial partial pressure of oxygen (Fig. 1).
Fig. 1. Methemoglobin levels and arterial partial pressure of
oxygen of rats after the single intraperitoneal admin-
istration of 40 mg/kg NaNO2. The partial pressure of
oxygen of blood samples were determined within 15 min
after drawn from the cannulated femoral artery with
PE-50 tube. Data are mean ± SEM of four rats.Hypoxia Aggravates Fatty Liver to NASH
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Hepatic pathology in rats fed choline-deficient hyper-fat
diets and exposed to hypoxia
Histological examination of livers of rats fed CDHF for 8
weeks showed marked steatohepatitis (Fig. 2, CDHF group).
Fatty change was mostly a macrovesicular type, involving
all zones of the lobe. Inflammatory infiltrates consisted of
foci of acute and chronic inflammatory cells randomly dis-
tributed in the lobe. However, no liver fibrosis was present.
On the other hand, severe liver fibrosis was observed in rats
fed for 8 weeks on CDHF diets as well as NaNO2 treatment
during the last 4 weeks (CDHF + hypoxemia group), (Fig. 2,
right panel, stained with blue, CDHF + hypoxemia). Another
control group; rats exposed to hypoxia alone and provided
with normal diets showed no histopathological changes in
liver tissue (Fig. 2, Hypoxemia). In the next series of
experiments, the effects of the above histological changes on
various biological markers of liver function were examined.
Serum and liver biochemical parameters
Serum triglyceride levels were comparable in control and
hypoxemic rats (Table 1). On the other hand, at 8 weeks of
treatment, hepatic triglyceride levels were significantly
higher in CDHF and CDHF + hypoxemia rats than those fed
normal chew (Normal control group) or treated with NaNO2
Fig. 2. Histology of liver tissues of the experimental groups. Liver sections were stained with hematoxylin (left) and Masson
trichrome-stain (right). Note the extent of liver damage in the CDHF + hypoxemia rats.F. Takayama et al.
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alone (Hypoxemia group).
Body weights, blood glucose levels and survival rates at 8
weeks of treatment, are shown in Table 2. Body weights
were significantly lower in CDHF and CDHF + hypoxemia
rats than those fed normal chew (Normal control group) or
treated with NaNO2 alone (Hypoxemia group). The blood
glucose levels were not different between groups. Except
for one of five CDHF + hypoxemia rats, all rats were alive
at the end of the experimental period.
Biochemical marker of liver fibrosis
Serial measurements of serum hyaluronic acid showed no
changes in its level at 4 weeks of control diets, CDHF alone,
and hypoxemia alone. However, switching to the combina-
tion of CDHF and hypoxemia at week 4 gradually and
significantly increased serum hyaluronic acid levels, which
rose to 2.5-fold those of rats of other groups at 8 weeks of
treatment (Fig. 3).
Changes in hepatobiliary enzymes
Serum levels of both AST and ALT were significantly
higher in the CDHF and CDHF + hypoxemia rats compared
with the control and hypoxemia groups (Fig. 4A). In
particular, AST and ALT levels in CDHF + hypoxemia
rats were 5-fold and 2.7-fold higher, respectively, than the
control group. Furthermore, serum ALP activity was signifi-
cantly higher at 8 weeks in CDHF and CDHF + hypoxemia
groups, compared with the other two groups (Fig. 4B).
However, γ-GTP activity was only significantly increased
in the CDHF + hypoxemia group, compared with the other
groups (Fig. 4B).
Discussion
NASH can be associated with progressive hepatic fibrosis
and is characterized by histopathological changes resembling
alcohol-like liver damage in the absence of alcohol abuse.
Several animal models of steatosis exist, but few models of
steatohepatitis are available.
Table 1. Triglyceride levels in plasma and liver of rats fed con-
trol diets or choline-deficient hyper-fat diets with or
without hypoxemic stress
Each value represents the mean ± SEM for five rats. Data were
statistically analyzed by one-way analysis of variance (ANOVA)
with Dunnet’s multiple comparison test. **p<0.01 vs Normal
control group, ††p<0.01 vs Hypoxemia group.
Group
plasma 
(mg/ml)
liver 
(mg/g wet weight)
Normal control 0.661 ± 0.049 2.439 ± 0.249
CDHF 0.418 ± 0.055 22.017 ± 1.694**
CDHF + hypoxemia 0.442 ± 0.090 17.787 ± 2.216**,††
Hypoxemia 0.650 ± 0.051 2.244 ± 0.187
Table 2. Body weights, blood glucose levels and survival of rats fed control diets or choline
deficient hyper-fat diets with or without hypoxemia stress
Normal control and Hypoxemia rats were fed on standard diets without and with hypoxemia
stress, respectively. CDHF and CDHF + hypoxemia rats were fed on choline deficient hyper-
fat (CDHF) diets without and with hypoxemia stress, respectively. Each value represents the
mean ± SEM or the mean or five rats. Data were statistically analyzed by one-way analysis of
variance (ANOVA) techniques with Dunnet’s multiple comparison procedures. ##p<0.01 vs
Normal control group, ††p<0.01 vs Hypoxemia group.
Group
body weght 
(g/body)
blood glucose 
(mg/dL)
survival 
(%)
Normal control 307.3 ± 6.7 115.6 ± 7.8 100
CDHF 209.8 ± 6.2## 110.6 ± 9.7 100
CDHF + hypoxemia 217.8 ± 13.6##,†† 120.3 ± 14.6 80
Hypoxemia 313.2 ± 6.7 117.4 ± 11.6 100
Fig. 3. Serial changes in serum hyaluronic acid levels in the
four rat groups. Data are mean ± SEM of five rats in
each group. *p<0.05, **p<0.01 vs the value at 2 weeks
for the corresponding group (by ANOVA followed by
with Dunnett’s multiple comparison test).Hypoxia Aggravates Fatty Liver to NASH
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Although the pathogenesis of NASH has not yet been
fully elucidated, the “two-hit” theory is now accepted [12].
The first hit is the accumulation of fatty acids in the liver
caused by several mechanisms (steatosis). Steatosis is rela-
tively mild pathological process and is easily reversible.
However, with secondary cellular stress (e.g., oxidative
stress, endotoxin-mediated cytokine release), steatosis can
progress to steatohepatitis, which is characterized by inflam-
mation, necrosis, and fibrosis; i.e., a chronic liver disease
[13, 14].
A methionine-choline deficiency model was used for
NASH, because the changes induced in the liver are
reproducible, rapid and similar to those observed in NASH
[7, 15, 16]. In our attempt to develop a NASH model, we
were able to induce steatosis in rats fairly easily by feeding
them at the age of 4 weeks CDHF diets continuously for 4
weeks. In the next step, we considered that oxidative stress
produced by different methods could induce liver damage,
similar to the reported hypoxemic-related liver injury in
patients with OSA [8]. In fact, there is evidence to suggest
that liver injury in OSA is the direct result of hypoxemia
rather than ischemia [9,  10]. Several studies argued that
hypoxemia could play a role in the pathogenesis of NASH,
[17, 18] suggesting that NASH represents tissue hypoxemia
in fatty liver.
In this study, rats fed CDHF diets for 4 weeks followed by
another 4 weeks of the same diets combined with 40 mg/kg
NaNO2 demonstrated significant fatty deposits and leuko-
cytic infiltration in the liver. Severe liver fibrosis was only
observed in the CDHF + hypoxemia rats. Thus, by feeding
rats a CDHF diet combined with NaNO2, we reproduced
the typical hepatic lesions of NASH, namely, steatosis,
inflammation, and early fibrosis, as indicated by a significant
increase in triglyceride, hyaluronic acid, AST, ALT and
γ-GTP.
We reported previously that hypoxemia was produced
by administration of NaNO2 [ 11]. Indeed, nitrite is now
being recognized as a critical ‘hypoxic buffer’, potentially
contributing to the regulation of hypoxic vasodilatation
and hypoxic mitochondrial respiration [19]. As well known,
the methemoglobin cannot possess oxygen capacity, its
increase in the blood, results in hypoxia. As shown Fig. 1,
the arterial partial pressure of oxygen decreased to approxi-
mately 40 mmHg within 15 min from injection, thereafter
1 h later, recovered to approximately 60 mmHg, the criteria
level of the human respiratory failure. The NaNO2 injections
were performed everyday, there rats were exposed to
recurrent and intermittent hypoxia, in other words, repetitive
cycles of hypoxia and reoxygenation, for 4 weeks. That is
considered similar to recurrent ischemia-reperfusion (mild
or moderate) led to oxidative stress in the liver, from the
viewpoint of oxygen supply.
Although this study did not examine how the hypoxia
induced liver fibrosis in the rats with simple fatty liver,
and not in the controls, we suppose that resulted from the
vulnerability of fatty liver to recurrent and intermittent
hypoxia. Fatty liver may reduce tolerance to ischemia-
reperfusion injury. There are experimental studies that have
indicated vulnerability of fatty hepatocytes to anoxic injury
[20], and have shown the increased sensitivity to anoxia is
caused by the fatty metamorphosis, when compared with
normal liver parenchymal cells. The hypoxemia exposure to
fatty liver leads to hepatocytes swelling via oxidative stress
mechanisms, in there may proceed NF-κB activation inflam-
matory reaction and fibrosis.
Due to its high water-solubility, NaNO2 is mainly excreted
via the kidney. We also confirmed histologically and
biochemically that daily systemic injection of NaNO2
(40 mg/kg/day) did not cause any renal injury or dysfunction
(data not shown).
Our new rat model of NASH might be useful for the
development of therapeutic agents against NASH. In addi-
Fig. 4. Biochemical markers in serum for the hepatobiliary
damages: AST and ALT levels (A), ALP and γ-GTP
levels (B), in the four experimental groups measured at
the end of the study period. Each value represents the
mean ± SEM of five rats. #p<0.05, ##p<0.01 vs Normal
control group, *p<0.05, **p<0.01 vs CDHF group,
†p<0.05,  ††p<0.01 vs Hypoxemia group (by ANOVA
followed by with Dunnett’s multiple comparison test).F. Takayama et al.
J. Clin. Biochem. Nutr.
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tion, this model (PCT/JP 2007/52477) suggests that patients
with severe OSA could have subclinical steatosis and liver
fibrosis.
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